Please assess the completion status of the following clinical trial:

Trial Title: Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~* Infant of either gender, aged 50 to 70 days inclusive~* Mother is negative for HBsAg~* Born at full term of pregnancy (≥37 weeks) and with a birth weight ≥2.5 kg~* Written informed consent form signed by at least one parent or by another legal representative and an independent witness~* Parent/legal representative able to attend scheduled visits and to comply with the trial procedures during the entire duration of the trial.~Exclusion Criteria :~* Axillary temperature ≥37.1°C on the day of inclusion~* Current or planned enrolment in another clinical trial during the clinical trial period~* Known mother's history of Human Immunodeficiency Virus (HIV) infection~* Known immunodeficiency (congenital or acquired) or induced by immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy since birth, or systemic corticosteroids in the last 4 weeks (≥0.5 mg per kilogram and per day equivalent prednisolone and lasting more than 7 days)~* Receipt of blood-derived products since birth~* Acute symptoms or severe chronic illness (e.g. cardiac, renal insufficiency, diabetes, auto immune disorders, congenital defect) that may interfere with conduct or completion of trial~* Occurrence of seizures since birth~* Hypersensitivity to any of the vaccine components~* Coagulopathy contraindicating intramuscular injection~* History of (documented) clinical or serological/microbiological confirmed infection due to pertussis, tetanus, diphtheria, polio, Haemophilus influenzae type b (Hib) or hepatitis B (HB) diseases~* History of vaccination against pertussis, tetanus, diphtheria, polio, Hib or HB infections~* Vaccination within the last 4 weeks.

- Gender: ALL
- Minimum Age: 50 Days
- Maximum Age: 70 Days
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): DTaP IPV HB-PRP\~T vaccine group
- 2 (Type: ACTIVE_COMPARATOR): PENTAXIM™ and ENGERIX B® vaccines group

Based on this trial design, predict the completion outcome and termination type (if applicable).